SUPPLEMENTARY FIGURE S 1 LEGEND Supplementary Fig S
- Slides: 10
SUPPLEMENTARY FIGURE S 1 LEGEND Supplementary Fig. S 1. Scatter plots of MRM quantitation data using pooling serum and individual serum from healthy control group, before HCC treatment group, and after HCC treatment group. Left panel represents pooled serum from healthy control group, before HCC treatment group, and after HCC treatment group. Error bars represent the standard deviations from 5 technical replicates. Horizontal bars indicate the average serum level of the protein; Pvalues were calculated by ANOVA. Right panels indicate individual samples. See also Supplementary Table S 4 and Supplementary Figure S 2
Supplementary Figure S 1. As a result of the MRM analysis, a list of the 9 proteins where the expression profile of pooling specimen and individual specimen match with each other. 1. Very long-chain specific acyl-Co. A dehydrogenase, mitochondria (ACADVL) Pooled serum Individual serum AAQAPSSFQLLYDLK Healthy control Before HCC treatment Average STDEV CV (%) 5. 84 0. 72 12. 40 Healthy control vs. Before HCC treatment Fold change 8. 89 0. 29 3. 30 1. 52 AAQAPSSFQLLYDLK After HCC treatment 4. 46 0. 89 19. 88 Before HCC treatment vs. After HCC treatment 1. 99 Average STDEV CV (%) Healthy control Before HCC treatment 0. 55 0. 20 36. 49 Meaningful difference ( p < 0. 05) After HCC treatment 0. 71 0. 23 32. 94 0. 44 0. 36 82. 65 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes
2. Actin binding protein, anillin (ANLN) Pooled serum Individual serum TQSLPVTEK Healthy control Before HCC treatment Average STDEV CV (%) 0. 19 0. 04 23. 64 Healthy control vs. Before HCC treatment Fold change TQSLPVTEK 0. 82 0. 03 3. 72 4. 37 After HCC treatment 0. 73 0. 21 29. 16 Before HCC treatment vs. After HCC treatment 1. 11 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 3. 49 1. 74 49. 88 After HCC treatment 6. 29 1. 51 24. 08 3. 56 2. 88 80. 73 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes
3. Brain acid soluble protein 1 (BASP 1) Pooled serum Individual serum AEGAATEEEGTPK Average STDEV CV (%) Fold change Healthy control Before HCC treatment 107. 18 5. 25 4. 89 24. 84 3. 76 15. 12 Healthy control vs. Before HCC treatment 0. 23 AEGAATEEEGTPK After HCC treatment 8. 63 0. 79 9. 12 Before HCC treatment vs. After HCC treatment 2. 88 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 14. 01 16. 40 117. 08 After HCC treatment 3. 10 1. 24 40. 01 1. 88 1. 29 68. 36 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes No
4. C-1 -tetrahydrofolate synthase, cytoplasmic (MTHFD 1) Pooled serum Individual serum TDTESELDLISR Healthy control Average STDEV CV (%) Before HCC treatment 0. 27 0. 02 7. 75 9. 36 0. 98 10. 45 Healthy control vs. Before HCC treatment Fold change TDTESELDLISR 34. 98 After HCC treatment 5. 49 1. 31 23. 80 Before HCC treatment vs. After HCC treatment 1. 70 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 0. 62 0. 37 59. 43 After HCC treatment 0. 85 0. 46 54. 22 0. 45 106. 50 Healthy control vs. Before HCC treatment vs. After HCC treatment No Yes
5. Calpain-1 catalytic subunit (CAPN 1) Average STDEV CV (%) Fold change Pooled serum Individual serum YLGQDYEQLR Healthy control Before HCC treatment After HCC treatment 1. 07 0. 08 7. 72 0. 64 0. 10 15. 00 0. 32 0. 02 4. 79 Healthy control vs. Before HCC treatment vs. After HCC treatment 0. 60 2. 02 Average STDEV CV (%) Healthy control Before HCC treatment After HCC treatment 0. 23 0. 07 30. 36 0. 11 0. 05 46. 80 0. 09 0. 07 86. 66 Meaningful difference ( p < 0. 05) Healthy control vs. Before HCC treatment vs. After HCC treatment Yes No
6. Complementary C 4 -A (C 4 A) Average STDEV CV (%) Fold change Pooled serum Individual serum VGDTLNLNLR Healthy control Before HCC treatment 7. 21 0. 56 7. 80 4. 61 1. 26 27. 34 Healthy control vs. Before HCC treatment 0. 64 After HCC treatment 1. 41 0. 08 5. 91 Before HCC treatment vs. After HCC treatment 3. 27 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 1. 49 0. 60 40. 40 After HCC treatment 0. 72 0. 44 60. 76 0. 40 0. 38 93. 85 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes No
7. Alpha-fetoprotein (AFP) Pooled serum Individual serum GYQELLEK Healthy control Average STDEV CV (%) Before HCC treatment 0. 39 0. 04 9. 11 5. 07 0. 58 11. 43 Healthy control vs. Before HCC treatment Fold change GYQELLEK 12. 90 After HCC treatment 0. 47 0. 07 15. 23 Before HCC treatment vs. After HCC treatment 10. 87 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 0. 73 0. 30 43. 49 After HCC treatment 1. 01 0. 24 23. 95 0. 60 0. 49 81. 51 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes
8. Filamin-B (FLNB) Pooled serum Individual serum APLNVQFNSPLPGDAVK Healthy control Average STDEV CV (%) Before HCC treatment 0. 22 0. 02 8. 86 0. 28 0. 02 5. 66 Healthy control vs. Before HCC treatment Fold change 1. 27 APLNVQFNSPLPGDAVK After HCC treatment 0. 15 0. 02 11. 72 Before HCC treatment vs. After HCC treatment 1. 87 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 0. 53 0. 25 48. 07 After HCC treatment 0. 67 0. 19 27. 86 0. 40 0. 33 82. 75 Healthy control vs. Before HCC treatment vs. After HCC treatment No Yes
9. Polyadenylate-binding protein 1 (PABPC 1) Average STDEV CV (%) Fold change Pooled serum Individual serum EFSPFGTITSAK Healthy control Before HCC treatment 2. 38 0. 16 6. 89 1. 73 0. 23 13. 21 Healthy control vs. Before HCC treatment 0. 73 After HCC treatment 0. 65 0. 08 12. 30 Before HCC treatment vs. After HCC treatment 2. 67 Healthy control Average STDEV CV (%) Meaningful difference ( p < 0. 05) Before HCC treatment 0. 43 0. 15 34. 48 After HCC treatment 0. 18 0. 10 53. 57 0. 14 0. 12 84. 49 Healthy control vs. Before HCC treatment vs. After HCC treatment Yes No
